AMGN vs RYTM
AMGN: Amgen is a leading biotechnology firm dedicated to developing innovative human therapeutics to address critical unmet needs in areas like oncology, inflammation, and cardiovascular disease. RYTM: Rhythm Pharmaceuticals is a biopharmaceutical company specializing in precision therapies for rare genetic and neuroendocrine disorders characterized by severe obesity and hyperphagia.
Side-by-side fundamentals
| Metric | AMGN | RYTM | Edge |
|---|---|---|---|
| Price as of 2026-08-11 close | $414.30 | $112.85 | |
| Market cap as of 2026-08-12 | $224.0B | $7.8B | |
| P/E as of 2026-08-12 | 25.41 | n/a | |
| PEG as of 2026-08-12 | 5.48 | -3.21 | RYTM lower |
| Net margin as of 2026-08-12 | +22.9% | -85.6% | AMGN higher |
| Gross margin as of 2026-08-12 | +74.3% | +70.9% | AMGN higher |
| Operating margin as of 2026-08-12 | +30.3% | -83.6% | AMGN higher |
| ROE as of 2026-08-12 | +89.3% | -80.5% | AMGN higher |
| ROA as of 2026-08-12 | +9.5% | -44.0% | AMGN higher |
| Debt / equity as of 2026-08-12 | 4.90 | 0.49 | RYTM lower |
| Revenue growth (YoY) as of 2026-08-12 | +9.1% | +53.5% | RYTM higher |
| Revenue CAGR (3y) SEC XBRL | +11.8% | +100.2% | RYTM higher |
| Dividend yield as of 2026-08-12 | +2.4% | n/a | |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-08-12 | 0.41 | 2.00 | |
| 1-year return as of 2026-08-11 close | +45.3% | +19.7% | AMGN higher |
Fundamentals: market data, as of 2026-08-12. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-11.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.